chemieunternehmen.com

Evotec AG announced today that its multi-target endometriosis alliance with Bayer has reached another key pre-clinical milestone for the transition of a project from the alliance portfolio into pre-clinical development. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-further-important-pre-clinical-milestone-in-endometriosis-alliance-with-bayer-5396

Evotec AG today announced a multi-target collaboration with C4X Discovery Holdings plc („C4XD“). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-into-strategic-multi-target-alliance-with-c4x-discovery-5394

Evotec AG announced today that the Company has entered into a research collaboration with Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research („Inserm“). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-into-a-research-collaboration-with-inserm-in-oncology-5392

Evotec AG today announced that Evotec and Bayer have entered into a five-year, multi-target research partnership in kidney disease.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-bayer-partner-to-develop-new-treatments-to-fight-kidney-diseases-5387

Evotec AG today reported financial results and corporate updates for the first half of 2016. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-results-of-first-half-of-2016-5384

Evotec AG announced today that it has reached a milestone from Bayer for the progression of a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-clinical-development-milestone-as-part-of-its-multi-target-alliance-with-bayer-in-endometriosis-5382

Evotec AG announced today a collaboration with Antibiotic Research UK („ANTRUK“) to identify alternative means of treating infections that are resistant to currently available antibiotics. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-awarded-contract-from-antibiotic-research-uk-to-begin-integrated-drug-discovery-collaboration-5376

Evotec AG announced today that the Company has entered into a non-exclusive licence agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-license-agreement-for-access-to-crispr-cas9-gene-editing-technology-5374

Evotec AG announced today that the investment company Ellersbrook GmbH & Co. KG, („Ellersbrook“), Germany, will invest into Evotec’s internal TargetNASH programme.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-ellersbrook-join-forces-to-accelerate-targetnash-5372